STOCK TITAN

KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

KYNTRA BIO, INC. director Ho Maykin received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. They vest in four equal quarterly installments from the grant date, and this filing shows 7,000 options held directly after the award.

Positive

  • None.

Negative

  • None.
Insider Ho Maykin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 7,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 7,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 7,000 options Stock Option (Right to Buy) grant to director Ho Maykin
Exercise price $7.13 per share Exercise price of stock options on common stock
Expiration date June 11, 2036 Option term endpoint for 7,000 granted options
Shares underlying options 7,000 shares Underlying common stock covered by the option grant
Post-transaction derivative holdings 7,000 options Total options held directly after this grant
Stock Option (Right to Buy) financial
"Security title is listed as "Stock Option (Right to Buy)" for 7,000 shares."
exercise price financial
"The conversion or exercise price of the options is reported as 7.1300 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to the option shall vest in four equal quarterly installments from the grant date."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The options carry an expiration date of 2036-06-11 for the granted award."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ho Maykin

(Last)(First)(Middle)
C/O KYNTRA BIO, INC.
350 BAY STREET, SUITE 100, #6009

(Street)
SAN FRANCISCO CALIFORNIA 94133

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.1306/12/2026A7,000 (1)06/11/2036Common Stock7,000$07,000D
Explanation of Responses:
1. The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.
/s/ John Alden, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KYNTRA BIO (KYNB) report for Ho Maykin?

KYNTRA BIO reported that director Ho Maykin received a grant of stock options for 7,000 shares of common stock. These options are a compensation award, not an open-market purchase, and give the right to buy shares at a fixed exercise price in the future.

How many KYNTRA BIO (KYNB) stock options were granted and at what price?

Ho Maykin was granted 7,000 stock options, each with an exercise price of $7.13 per share. The grant price itself is $0.00, reflecting a typical equity compensation award, with value realized only if the stock trades above the exercise price later.

When do Ho Maykin’s KYNTRA BIO (KYNB) stock options vest?

The 7,000 stock options vest in four equal quarterly installments starting from the grant date. This means 25% of the options become exercisable every quarter over a one-year period, aligning ongoing vesting with continued service as a director at the company.

When do the granted KYNTRA BIO (KYNB) stock options expire?

The granted stock options expire on June 11, 2036, giving Ho Maykin roughly a decade to exercise them after vesting. If they are not exercised by the expiration date, the right to purchase the underlying 7,000 common shares will lapse entirely.

Is Ho Maykin buying or selling KYNTRA BIO (KYNB) shares in this Form 4?

This Form 4 does not show any open-market buying or selling of KYNTRA BIO shares. It reports a compensation-related grant of 7,000 stock options, a non-cash award that provides the right to buy shares later, subject to vesting and the $7.13 exercise price.